BioDelivery gets $27 million milestone for Onsolis approval from Meda
This article was originally published in Scrip
Executive Summary
BioDelivery Sciences has received almost $27 million in milestone payments from its commercial partner Meda in connection with the US approval of BioDelivery's breakthrough cancer pain product Onsolis (